Forsta AP Fonden Has $13.14 Million Position in Insulet Corporation $PODD

Forsta AP Fonden increased its position in Insulet Corporation (NASDAQ:PODD) by 53.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 46,220 shares of the medical instruments supplier’s stock after acquiring an additional 16,120 shares during the quarter. Forsta AP Fonden’s holdings in Insulet were worth $13,138,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PODD. Larson Financial Group LLC increased its stake in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the period. Elyxium Wealth LLC acquired a new position in shares of Insulet in the fourth quarter valued at approximately $28,000. Fideuram Asset Management Ireland dac acquired a new position in shares of Insulet in the fourth quarter valued at approximately $41,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Insulet in the third quarter valued at approximately $49,000. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Insulet in the second quarter valued at approximately $51,000.

Analysts Set New Price Targets

Several research analysts have recently issued reports on PODD shares. Benchmark reaffirmed a “buy” rating on shares of Insulet in a research note on Wednesday. Robert W. Baird lowered their price target on shares of Insulet from $360.00 to $248.00 in a report on Thursday, May 7th. JPMorgan Chase & Co. lowered their price target on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Royal Bank Of Canada restated an “outperform” rating and set a $280.00 price target on shares of Insulet in a report on Wednesday, May 27th. Finally, Raymond James Financial lowered their price target on shares of Insulet from $355.00 to $263.00 in a report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $252.04.

Insulet Price Performance

Insulet stock opened at $144.94 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 52-week low of $140.63 and a 52-week high of $354.88. The firm has a 50 day moving average price of $183.55 and a two-hundred day moving average price of $244.77. The firm has a market cap of $10.04 billion, a price-to-earnings ratio of 33.71, a PEG ratio of 1.14 and a beta of 1.13.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts predict that Insulet Corporation will post 6.44 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.